How much did Biosynex achieve in EBIT for the current year?
In the current year, Biosynex has achieved an EBIT of 618,000 EUR.
Biosynex EBIT 2024
Biosynex EBIT
618,000 EUR
Ticker
ALBIO.PA
ISIN
FR0011005933
WKN
A1H8G1
In 2024, Biosynex's EBIT was 618,000 EUR, a -101.65% increase from the -37.4 M EUR EBIT recorded in the previous year.
The Biosynex EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2025e | 5.97 |
| 2024e | 0.62 |
| 2023 | -37.4 |
| 2022 | 38.8 |
| 2021 | 140.6 |
| 2020 | 45.4 |
| 2019 | 1.2 |
| 2018 | - |
| 2017 | 0.8 |
| 2016 | 0.7 |
| 2015 | -0.7 |
| 2014 | -0.7 |
| 2013 | -1.1 |
| 2012 | -0.8 |
| 2011 | -0.4 |
| 2010 | -0.1 |
| 2009 | -0.2 |
| 2008 | -0.2 |
| 2007 | -0.3 |
| 2006 | -0.2 |
Biosynex Revenue, EBIT, Net Income FR0011005933 · A1H8G1
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Biosynex, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biosynex from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biosynex’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Biosynex. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Biosynex’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Biosynex’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biosynex’s growth potential.
Biosynex Revenue, EBIT and net profit per share
| Date | Biosynex Revenue | Biosynex EBIT | Biosynex Net Income |
|---|---|---|---|
| 2025e | 146.47 M undefined | 5.97 M undefined | 5.1 M undefined |
| 2024e | 127.31 M undefined | 618,000 undefined | 886,698.1 undefined |
| 2023 | 92.98 M undefined | -37.4 M undefined | -37.12 M undefined |
| 2022 | 196.6 M undefined | 38.8 M undefined | 15.6 M undefined |
| 2021 | 382.5 M undefined | 140.6 M undefined | 104 M undefined |
| 2020 | 153.9 M undefined | 45.4 M undefined | 31.4 M undefined |
| 2019 | 34.2 M undefined | 1.2 M undefined | 1.1 M undefined |
| 2018 | 31.2 M undefined | 0 undefined | 500,000 undefined |
| 2017 | 30.5 M undefined | 800,000 undefined | 300,000 undefined |
| 2016 | 27 M undefined | 700,000 undefined | -100,000 undefined |
| 2015 | 9.9 M undefined | -700,000 undefined | -400,000 undefined |
| 2014 | 4.1 M undefined | -700,000 undefined | -1.5 M undefined |
| 2013 | 1.8 M undefined | -1.1 M undefined | -1.8 M undefined |
| 2012 | 1.5 M undefined | -800,000 undefined | -700,000 undefined |
| 2011 | 1.1 M undefined | -400,000 undefined | -300,000 undefined |
| 2010 | 1 M undefined | -100,000 undefined | 0 undefined |
| 2009 | 700,000 undefined | -200,000 undefined | -200,000 undefined |
| 2008 | 500,000 undefined | -200,000 undefined | -200,000 undefined |
| 2007 | 200,000 undefined | -300,000 undefined | -300,000 undefined |
| 2006 | 100,000 undefined | -200,000 undefined | -100,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 100,000 EUR | -200,000 EUR | -100,000 EUR |
| 2007 | 200,000 EUR | -300,000 EUR | -300,000 EUR |
| 2008 | 500,000 EUR | -200,000 EUR | -200,000 EUR |
| 2009 | 700,000 EUR | -200,000 EUR | -200,000 EUR |
| 2010 | 1 M EUR | -100,000 EUR | 0 EUR |
| 2011 | 1.1 M EUR | -400,000 EUR | -300,000 EUR |
| 2012 | 1.5 M EUR | -800,000 EUR | -700,000 EUR |
| 2013 | 1.8 M EUR | -1.1 M EUR | -1.8 M EUR |
| 2014 | 4.1 M EUR | -700,000 EUR | -1.5 M EUR |
| 2015 | 9.9 M EUR | -700,000 EUR | -400,000 EUR |
| 2016 | 27 M EUR | 700,000 EUR | -100,000 EUR |
| 2017 | 30.5 M EUR | 800,000 EUR | 300,000 EUR |
| 2018 | 31.2 M EUR | 0 EUR | 500,000 EUR |
| 2019 | 34.2 M EUR | 1.2 M EUR | 1.1 M EUR |
| 2020 | 153.9 M EUR | 45.4 M EUR | 31.4 M EUR |
| 2021 | 382.5 M EUR | 140.6 M EUR | 104 M EUR |
| 2022 | 196.6 M EUR | 38.8 M EUR | 15.6 M EUR |
| 2023 | 92.98 M EUR | -37.4 M EUR | -37.12 M EUR |
| 2024e | 127.31 M EUR | 618,000 EUR | 886,698.1 EUR |
| 2025e | 146.47 M EUR | 5.97 M EUR | 5.1 M EUR |
Biosynex stock margins FR0011005933 · A1H8G1
The Biosynex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biosynex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biosynex.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Biosynex's sales revenue. A higher gross margin percentage indicates that the Biosynex retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Biosynex's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Biosynex's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biosynex's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biosynex. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biosynex's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Biosynex Margin History
| Biosynex Gross margin | Biosynex Profit margin | Biosynex EBIT margin | Biosynex Profit margin |
|---|---|---|---|
| 2025e | 52.84 % | 4.08 % | 3.48 % |
| 2024e | 52.84 % | 0.49 % | 0.7 % |
| 2023 | 52.84 % | -40.23 % | -39.93 % |
| 2022 | 52.03 % | 19.74 % | 7.93 % |
| 2021 | 53.96 % | 36.76 % | 27.19 % |
| 2020 | 45.03 % | 29.5 % | 20.4 % |
| 2019 | 57.02 % | 3.51 % | 3.22 % |
| 2018 | 51.92 % | 0 % | 1.6 % |
| 2017 | 50.16 % | 2.62 % | 0.98 % |
| 2016 | 52.59 % | 2.59 % | -0.37 % |
| 2015 | 56.57 % | -7.07 % | -4.04 % |
| 2014 | 56.1 % | -17.07 % | -36.59 % |
| 2013 | 77.78 % | -61.11 % | -100 % |
| 2012 | 73.33 % | -53.33 % | -46.67 % |
| 2011 | 81.82 % | -36.36 % | -27.27 % |
| 2010 | 80 % | -10 % | 0 % |
| 2009 | 71.43 % | -28.57 % | -28.57 % |
| 2008 | 80 % | -40 % | -40 % |
| 2007 | 100 % | -150 % | -150 % |
| 2006 | 100 % | -200 % | -100 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 100 % | -200 % | -100 % |
| 2007 | 100 % | -150 % | -150 % |
| 2008 | 80 % | -40 % | -40 % |
| 2009 | 71.43 % | -28.57 % | -28.57 % |
| 2010 | 80 % | -10 % | 0 % |
| 2011 | 81.82 % | -36.36 % | -27.27 % |
| 2012 | 73.33 % | -53.33 % | -46.67 % |
| 2013 | 77.78 % | -61.11 % | -100 % |
| 2014 | 56.1 % | -17.07 % | -36.59 % |
| 2015 | 56.57 % | -7.07 % | -4.04 % |
| 2016 | 52.59 % | 2.59 % | -0.37 % |
| 2017 | 50.16 % | 2.62 % | 0.98 % |
| 2018 | 51.92 % | 0 % | 1.6 % |
| 2019 | 57.02 % | 3.51 % | 3.22 % |
| 2020 | 45.03 % | 29.5 % | 20.4 % |
| 2021 | 53.96 % | 36.76 % | 27.19 % |
| 2022 | 52.03 % | 19.74 % | 7.93 % |
| 2023 | 52.84 % | -40.23 % | -39.93 % |
| 2024e | 52.84 % | 0.49 % | 0.7 % |
| 2025e | 52.84 % | 4.08 % | 3.48 % |
Biosynex Aktienanalyse
What does Biosynex do?
The company Biosynex SA was founded in 2005 in Strasbourg, France. The company is a manufacturer and distributor of diagnostic test kits used for the rapid and accurate diagnosis of various infectious diseases and other health conditions. Biosynex SA has established itself as a leading player in the global health market in recent years. The business model of Biosynex SA includes the design, manufacture, and distribution of various medical diagnostic tests that are capable of quickly and efficiently detecting pathogens and other health conditions. The company offers a wide range of medical test kits that can be used for the diagnosis of HIV/AIDS, hepatitis C, syphilis, rapid pregnancy tests, menopause, bleeding during pregnancy, vitamin D deficiency, and many other health conditions. The main focus of Biosynex SA is on developing test kits that are easy to use and provide accurate and reliable results. With its technological know-how and collaboration with leading experts in the field of medical diagnostics, Biosynex SA has taken a leading position in the development and marketing of medical diagnostic test kits. By collaborating with doctors, hospitals, and clinics globally, Biosynex SA has successfully expanded its business. Biosynex SA has various business areas specifically focused on the marketing and distribution of medical diagnostic tests. The most well-known areas include gynecology, infectious diseases, and pediatrics. Biosynex SA also has a strong presence in the global market, including Asia, Europe, Africa, and America. One of the most well-known products of Biosynex SA is the HIV self-test called Autotest VIH®, which is available in many European countries and North America. The test kit is CE marked and approved by leading health authorities such as the WHO and the EU. The product is an important tool in reducing the spread of HIV infections and allowing people to make a confidential diagnosis of HIV/AIDS in a private setting. In the field of gynecology, Biosynex SA offers various products such as the Unistick® pregnancy test, Unistick® ovulation test, and Unistick® menopause test kit. These products enable women to easily and efficiently diagnose pregnancy, ovulation, and menopause. The test kits are easy to use, can be used at home, and provide results within minutes. In summary, Biosynex SA has earned its leading position in the global market due to its focus on innovative technology and high-quality product range. The company has made a significant contribution to improving healthcare worldwide with its expertise and commitment to diagnosing health conditions. Biosynex SA will continue to expand its business in the future to support even more people worldwide and further improve the quality of healthcare. Biosynex ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Biosynex's EBIT
Biosynex's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Biosynex's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Biosynex's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Biosynex’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Biosynex stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Biosynex.
How has the EBIT of Biosynex developed in recent years?
The EBIT of Biosynex has increased by -101.652% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Biosynex?
The EBIT of Biosynex is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Biosynex pay?
Over the past 12 months, Biosynex paid a dividend of 2 EUR . This corresponds to a dividend yield of about 52.22 %. For the coming 12 months, Biosynex is expected to pay a dividend of 0 EUR.
What is the dividend yield of Biosynex?
The current dividend yield of Biosynex is 52.22 %.
When does Biosynex pay dividends?
Biosynex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biosynex?
Biosynex paid dividends every year for the past 2 years.
What is the dividend of Biosynex?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biosynex located?
Biosynex is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biosynex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biosynex from 5/18/2022 amounting to 2 EUR, you needed to have the stock in your portfolio before the ex-date on 5/16/2022.
When did Biosynex pay the last dividend?
The last dividend was paid out on 5/18/2022.
What was the dividend of Biosynex in the year 2023?
In the year 2023, Biosynex distributed 2 EUR as dividends.
In which currency does Biosynex pay out the dividend?
The dividends of Biosynex are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biosynex
Our stock analysis for Biosynex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biosynex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
